Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will consist of multiple ascending oral doses in up to 3 groups, for 29 days.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| KQ-791 Dose 1 | Experimental | Single loading dose on day 1, followed by single doses on days 8, 15, 22, 29 |
|
| KQ-791 Dose 2 | Experimental | Single loading dose on day 1, followed by a daily dose for 28 days |
|
| KQ-791 Dose 3 | Experimental | Single loading dose on day 1 or days 1-2, followed by a daily dose for 28 days |
|
| Placebo | Placebo Comparator | Multiple ascending doses matching KQ-791 dose |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| KQ-791 | Drug | Capsules administered orally |
|
| Measure | Description | Time Frame |
|---|---|---|
| Difference in the Change From Baseline in Fasting Blood Glucose Between KQ-791 and Placebo | Data table is change from baseline in Fasting Blood Glucose. Statistical Analysis includes results for difference in Change from baseline in Fasting Blood Glucose Between KQ-791 and Placebo. | Baseline to Day 29 |
| Number of Participants With One or More Treatment-Emergent Adverse Events | Baseline to Day 29 |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in the Quantitative Insulin Sensitivity Check Index (QUICKI) | QUICKI = 1/(log FPG + log FPI) where FPG = fasting plasma glucose (mg/dL); FPI = fasting plasma insulin (estimated based on fasting serum insulin; (μIU/mL)). Lower numbers reflect greater insulin resistance. | Baseline to Day 29 |
Not provided
Inclusion Criteria:
Have a diagnosis of Type 2 Diabetes Mellitus (T2DM)
Be an adult between the ages of 18 (19 for Lincoln site) and 70 years
Female participants must be of non-childbearing potential, and must be either 1) postmenopausal with amenorrhea for at least 1 year prior to the first dose and Follicle Stimulating Hormone (FSH) serum levels consistent with postmenopausal status, or 2) have undergone one of the following sterilization procedures at least 6 months prior to the first dose:
Non-vasectomized males must agree to use a condom with spermicide or abstain from sexual intercourse during the study until 100 days beyond the last dose of study drug. (No restrictions are required for a vasectomized male provided his vasectomy has been performed 4 months or more prior to first dosing. A male who has been vasectomized less than 4 months prior to first dosing must follow the same restrictions as a non-vasectomized male)
Males must agree to not donate sperm during the study and for 100 days following the last dose
Have an HbA1c value between 7.0-10.0%
Be on a stable treatment regimen of metformin, with or without diet/exercise, for at least 8 weeks
Weigh 60 kilograms (kg) or more at screening and have a body mass index (BMI) greater than or equal to (≥) 25.0 and less than or equal to (≤) 40.0 kilograms/meters squared (kg/m2)
Have laboratory test results within the normal range for T2DM population, or with abnormalities deemed clinically insignificant. Urine protein levels must be within normal limits
Absence of active diabetic retinopathy (Stage 2 or greater by the International Clinical Disease Severity Scale for Diabetic Retinopathy)
Are willing to comply with specific dietary restrictions (that is, [i] able to fast overnight for at least 8-12 hours on several days and [ii] able to consume the standard meals provided during specified confinement days)
Have given written consent to allow collection of samples for Peripheral Blood Mononuclear Cells (PBMC) analysis and for possible biomarkers/safety analysis
Have given written informed consent approved by the institutional review board (IRB) governing the site
Exclusion Criteria:
Are currently enrolled in a clinical trial involving an investigational product or off-label use of a drug or device, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
Participated (defined as the last dose of study drug) within 30 days prior to dosing in a clinical trial involving an investigational product or non-approved use of a drug with a short half-life or within 5 half-lives of an investigational product with a half-life longer than 6 days
- Have a (QTcF) greater than (>) 450 milliseconds (msec), or clinical significant hypokalemia, a family history of long QT syndrome or any abnormality in the 12-lead Electrocardiogram (ECG)
Abnormal blood pressure (sitting) defined as diastolic blood pressure > 95 or less than (<) 50 millimeter of mercury (mmHg) and/or systolic blood pressure > 160 or < 90 mmHg
Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs
Show evidence of regular use of known drugs of abuse and/or positive findings on urinary drug screening
Evidence of human immunodeficiency virus (HIV) infection, hepatitis B, hepatitis C and/or positive results at screening for the respective antibodies for HIV, hepatitis B surface antigen (HBsAg), or hepatitis C antibodies (HCV)
Have anemia that would interfere with the trial or have donated ≥500 mL of blood within 56 days before the first dose or have donated plasma within 7 days before the first dose or provided any blood donation within last 30 days
Have an average weekly alcohol intake that exceeds 14 units per week (males) and 7 units per week (females) [1 unit = 12 ounces (oz) or 360 mL of beer, 5 oz or 150 mL of wine, or 1.5 oz or 45 mL of distilled spirits] or are unwilling to stop alcohol consumption 48 hours prior to the first dosing and throughout the study
Consume more than 10 cigarettes per day or the equivalent or are unable or unwilling to adhere to restricted smoking policies
Have had >1 episode of documented severe hypoglycemia within last 6 months or are currently diagnosed as having hypoglycemia unawareness
Have any of the following clinical laboratory test results:
Have used insulin or other glycemic control medications, except metformin, for diabetic control within 3 months
Intend to use non-steroidal anti-inflammatory drugs (except aspirin) and drugs known to prolong QT interval, herbal products, or vitamin supplements that change glucose levels. The following medications are allowed for participants:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Email: daniel.bouthillier@Kaneq.ca | Kaneq Bioscience | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Celerion | Tempe | Arizona | 85283 | United States | ||
| Clinical Pharmacology of Miami, Inc. |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | KQ-791 Dose 1 | Single loading dose of 100 mg on day 1, followed by single 50 mg doses on days 8, 15, 22, 29 KQ-791: Capsules administered orally |
| FG001 | KQ-791 Dose 2 | Single loading dose of 250 mg on day 1, followed by a daily dose of 25 mg for 28 days KQ-791: Capsules administered orally |
| FG002 | KQ-791 Dose 3 | Single loading dose of 1500 mg on day 1, followed by a daily dose of 150 mg for 28 days KQ-791: Capsules administered orally |
| FG003 | Placebo | Multiple ascending doses matching KQ-791 dose Placebo: Capsules administered orally |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | KQ-791 Dose 1 | Single loading dose of 100 mg on day 1, followed by single 50 mg doses on days 8, 15, 22, 29 KQ-791: Capsules administered orally |
| BG001 | KQ-791 Dose 2 | Single loading dose of 250 mg on day 1, followed by a daily dose of 25 mg for 28 days KQ-791: Capsules administered orally |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Difference in the Change From Baseline in Fasting Blood Glucose Between KQ-791 and Placebo | Data table is change from baseline in Fasting Blood Glucose. Statistical Analysis includes results for difference in Change from baseline in Fasting Blood Glucose Between KQ-791 and Placebo. | Pharmacodynamic (PD) population incudes all 81 participants | Posted | Mean | Standard Deviation | mg/dL milligrams per deciliters | Baseline to Day 29 |
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | KQ-791 Dose 1 | Single loading dose of 100 mg on day 1, followed by single 50 mg doses on days 8, 15, 22, 29 KQ-791: Capsules administered orally |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anaemia | Blood and lymphatic system disorders | MedDRA 18.0 | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Conjunctival irritation | Eye disorders | MedDRA 18.0 | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Gosse Bruinsma | Kaneq Bioscience Limited | 1-613-800-0955 | gosse.bruinsma@kaneqbioscience.ca |
Not provided
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | Capsules administered orally |
|
| Change From Baseline in the Insulin Sensitivity Index (ISI) |
Insulin sensitivity index (ISI) composite using Matsuda's whole body insulin sensitivity, ISI [composite] = 10000/√[(FPG x FPI)x(Mean Glucose 0-120min in MMTT x Mean Insulin 0-120 min in MMTT)] where MMTT is a mixed meal tolerance test, Hour 0=just prior dosing. Lower values indicate greater insulin resistance. |
| Baseline to Day 29 |
| Change From Baseline in Beta Cell Function | Evaluated as beta index = (Insulin Area Under the Effect Curve (AUEC) in MMTT/Glucose AUEC in MMTT) | Baseline to Day 29 |
| Change From Baseline in Disposition Index | Disposition Index evaluated as beta index x ISI [composite]. Lower values of the disposition index suggests loss of function of beta cells. | Baseline to Day 29 |
| Change From Baseline in the Hepatic Insulin Resistance Index | Hepatic Insulin Resistance Index will be evaluated as Glucose AUEC from zero to 30 minutes (AUEC0-30min) in MMTT x Insulin AUEC0-30 min in MMTT | Baseline to Day 29 |
| Change From Baseline in 7-point Average Blood Glucose | The 7-points measured were just prior to each meal and 90 minutes after the start of the meal and approximately bedtime. | Baseline to Day 29 |
| Change From Baseline in Postprandial Glucose | Baseline to Day 29 |
| Change From Baseline in HbA1c | Baseline to Day 29 |
| Area Under the Plasma Concentration-Time Curve From Time Zero to 24-hours Post-Dose (AUC0-24) | Pre-dose, 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose |
| Maximum Observed Plasma Concentration (Cmax) | Pre-dose, 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose |
| Time of the Maximum Measured Plasma Concentration (Tmax) | Pre-dose, 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose |
| Area Under the Plasma Concentration Versus Time Curve (AUCtau) | Pre-dose, 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose; Day 3, 8, 15, 22, 29, and up to 24 hours post-dose on Day 29 |
| Maximum Observed Plasma Concentration at Steady-state (Cmax_ss) | Pre-dose, 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose; Day 3, 8, 15, 22, 29, and up to 24 hours post-dose on Day 29 |
| Time of the Maximum Measured Plasma Concentration at Steady-state (Tmax_ss) | Pre-dose, 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose; Day 3, 8, 15, 22, 29, and up to 24 hours post-dose on Day 29 |
| Apparent Terminal Elimination Half-life (t1/2) | Pre-dose, 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose; Day 3, 8, 15, 22, 29, and up to 24 hours post-dose on Day 29 |
| Accumulation Index (AI) | Based on AUC (RacAUC), where RacAUC is the ratio of AUC during a dosing interval following the last dose over the loading dose (first dose) | Pre-dose, 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose; Day 3, 8, 15, 22, 29, and up to 24 hours post-dose on Day 29 |
| Miami |
| Florida |
| 33014 |
| United States |
| Orlando Clinical Research Center | Orlando | Florida | 32809 | United States |
| Celerion | Lincoln | Nebraska | 68502 | United States |
| BG002 | KQ-791 Dose 3 | Single loading dose of 1500 mg on day 1, followed by a daily dose of 150 mg for 28 days KQ-791: Capsules administered orally |
| BG003 | Placebo | Multiple ascending doses matching KQ-791 dose Placebo: Capsules administered orally |
| BG004 | Total | Total of all reporting groups |
| Participants |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| OG002 | KQ-791 Dose 3 | Single loading dose of 1500 mg on day 1, followed by a daily dose of 150 mg for 28 days KQ-791: Capsules administered orally |
| OG003 | Placebo | Multiple ascending doses matching KQ-791 dose Placebo: Capsules administered orally |
|
|
|
| Primary | Number of Participants With One or More Treatment-Emergent Adverse Events | PD population includes all 81 participants | Posted | Number | participants | Baseline to Day 29 |
|
|
|
| Secondary | Change From Baseline in the Quantitative Insulin Sensitivity Check Index (QUICKI) | QUICKI = 1/(log FPG + log FPI) where FPG = fasting plasma glucose (mg/dL); FPI = fasting plasma insulin (estimated based on fasting serum insulin; (μIU/mL)). Lower numbers reflect greater insulin resistance. | PD population includes all 81 participants | Posted | Mean | Standard Deviation | units on a scale | Baseline to Day 29 |
|
|
|
| Secondary | Change From Baseline in the Insulin Sensitivity Index (ISI) | Insulin sensitivity index (ISI) composite using Matsuda's whole body insulin sensitivity, ISI [composite] = 10000/√[(FPG x FPI)x(Mean Glucose 0-120min in MMTT x Mean Insulin 0-120 min in MMTT)] where MMTT is a mixed meal tolerance test, Hour 0=just prior dosing. Lower values indicate greater insulin resistance. | Includes all subjects who receive at least one dose of study drug and have evaluable ISI data. | Posted | Mean | Standard Deviation | units on a scale | Baseline to Day 29 |
|
|
|
| Secondary | Change From Baseline in Beta Cell Function | Evaluated as beta index = (Insulin Area Under the Effect Curve (AUEC) in MMTT/Glucose AUEC in MMTT) | PD population includes all 81 participants | Posted | Mean | Standard Deviation | (hr*μIU/mL(hr*mg/dL)) | Baseline to Day 29 |
|
|
|
| Secondary | Change From Baseline in Disposition Index | Disposition Index evaluated as beta index x ISI [composite]. Lower values of the disposition index suggests loss of function of beta cells. | Includes all subjects who receive at least one dose of study drug and have evaluable data for disposition index. | Posted | Mean | Standard Deviation | Index | Baseline to Day 29 |
|
|
|
| Secondary | Change From Baseline in the Hepatic Insulin Resistance Index | Hepatic Insulin Resistance Index will be evaluated as Glucose AUEC from zero to 30 minutes (AUEC0-30min) in MMTT x Insulin AUEC0-30 min in MMTT | PD population includes all 81 participants | Posted | Mean | Standard Deviation | (hr*mg/dL)*(hr*μUI/mL) | Baseline to Day 29 |
|
|
|
| Secondary | Change From Baseline in 7-point Average Blood Glucose | The 7-points measured were just prior to each meal and 90 minutes after the start of the meal and approximately bedtime. | PD population includes all 81 participants | Posted | Mean | Standard Deviation | mg/dL | Baseline to Day 29 |
|
|
|
| Secondary | Change From Baseline in Postprandial Glucose | PD population includes all 81 participants | Posted | Mean | Standard Deviation | hr*mg/dL | Baseline to Day 29 |
|
|
|
| Secondary | Change From Baseline in HbA1c | Includes all subjects who receive at least one dose of study drug and have evaluable HbA1c data. | Posted | Mean | Standard Deviation | Percentage of glycosylated hemoglobin | Baseline to Day 29 |
|
|
|
| Secondary | Area Under the Plasma Concentration-Time Curve From Time Zero to 24-hours Post-Dose (AUC0-24) | Includes all randomized subjects who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute AUC0-24. | Posted | Mean | Standard Deviation | ng*hr/mL | Pre-dose, 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose |
|
|
|
| Secondary | Maximum Observed Plasma Concentration (Cmax) | Includes all randomized subjects who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute Cmax. | Posted | Mean | Standard Deviation | ng/mL | Pre-dose, 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose |
|
|
|
| Secondary | Time of the Maximum Measured Plasma Concentration (Tmax) | Includes all randomized subjects who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute Tmax. | Posted | Mean | Standard Deviation | hours | Pre-dose, 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose |
|
|
|
| Secondary | Area Under the Plasma Concentration Versus Time Curve (AUCtau) | Includes all randomized subjects who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute AUCtau. | Posted | Mean | Standard Deviation | ng*hr/mL | Pre-dose, 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose; Day 3, 8, 15, 22, 29, and up to 24 hours post-dose on Day 29 |
|
|
|
| Secondary | Maximum Observed Plasma Concentration at Steady-state (Cmax_ss) | Includes all randomized subjects who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute Cmax_ss. | Posted | Mean | Standard Deviation | ng/mL | Pre-dose, 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose; Day 3, 8, 15, 22, 29, and up to 24 hours post-dose on Day 29 |
|
|
|
| Secondary | Time of the Maximum Measured Plasma Concentration at Steady-state (Tmax_ss) | Includes all randomized subjects who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute Tmax_ss. | Posted | Mean | Standard Deviation | hours | Pre-dose, 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose; Day 3, 8, 15, 22, 29, and up to 24 hours post-dose on Day 29 |
|
|
|
| Secondary | Apparent Terminal Elimination Half-life (t1/2) | Includes all randomized subjects who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute t1/2. | Posted | Mean | Standard Deviation | hours | Pre-dose, 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose; Day 3, 8, 15, 22, 29, and up to 24 hours post-dose on Day 29 |
|
|
|
| Secondary | Accumulation Index (AI) | Based on AUC (RacAUC), where RacAUC is the ratio of AUC during a dosing interval following the last dose over the loading dose (first dose) | Includes all randomized subjects who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute AI. | Posted | Mean | Standard Deviation | 1/h | Pre-dose, 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose; Day 3, 8, 15, 22, 29, and up to 24 hours post-dose on Day 29 |
|
|
|
| 0 |
| 20 |
| 12 |
| 20 |
| EG001 | KQ-791 Dose 2 | Single loading dose of 250 mg on day 1, followed by a daily dose of 25 mg for 28 days KQ-791: Capsules administered orally | 0 | 20 | 12 | 20 |
| EG002 | KQ-791 Dose 3 | Single loading dose of 1500 mg on day 1, followed by a daily dose of 150 mg for 28 days KQ-791: Capsules administered orally | 0 | 21 | 11 | 21 |
| EG003 | Placebo | Multiple ascending doses matching KQ-791 dose Placebo: Capsules administered orally | 1 | 20 | 14 | 20 |
| Dry eye | Eye disorders | MedDRA 18.0 | Systematic Assessment |
|
| Ocular discomfort | Eye disorders | MedDRA 18.0 | Systematic Assessment |
|
| Abdominal discomfort | Gastrointestinal disorders | MedDRA 18.0 | Systematic Assessment |
|
| Abdominal pain | Gastrointestinal disorders | MedDRA 18.0 | Systematic Assessment |
|
| Abdominal pain upper | Gastrointestinal disorders | MedDRA 18.0 | Systematic Assessment |
|
| Constipation | Gastrointestinal disorders | MedDRA 18.0 | Systematic Assessment |
|
| Diarrhoea | Gastrointestinal disorders | MedDRA 18.0 | Systematic Assessment |
|
| Dyspepsia | Gastrointestinal disorders | MedDRA 18.0 | Systematic Assessment |
|
| Eructation | Gastrointestinal disorders | MedDRA 18.0 | Systematic Assessment |
|
| Faeces discoloured | Gastrointestinal disorders | MedDRA 18.0 | Systematic Assessment |
|
| Nausea | Gastrointestinal disorders | MedDRA 18.0 | Systematic Assessment |
|
| Retching | Gastrointestinal disorders | MedDRA 18.0 | Systematic Assessment |
|
| Toothache | Gastrointestinal disorders | MedDRA 18.0 | Systematic Assessment |
|
| Vomiting | Gastrointestinal disorders | MedDRA 18.0 | Systematic Assessment |
|
| Fatigue | General disorders | MedDRA 18.0 | Systematic Assessment |
|
| Upper respiratory tract infection | Infections and infestations | MedDRA 18.0 | Systematic Assessment |
|
| Urinary tract infection | Infections and infestations | MedDRA 18.0 | Systematic Assessment |
|
| Arthropod bite | Injury, poisoning and procedural complications | MedDRA 18.0 | Systematic Assessment |
|
| Blood creatine phosphokinase increased | Investigations | MedDRA 18.0 | Systematic Assessment |
|
| Glomuerular filtration rate decreased | Investigations | MedDRA 18.0 | Systematic Assessment |
|
| Neutrophil count increased | Investigations | MedDRA 18.0 | Systematic Assessment |
|
| Hypoglycaemia | Metabolism and nutrition disorders | MedDRA 18.0 | Systematic Assessment |
|
| Arthralgia | Musculoskeletal and connective tissue disorders | MedDRA 18.0 | Systematic Assessment |
|
| Muscle twitching | Musculoskeletal and connective tissue disorders | MedDRA 18.0 | Systematic Assessment |
|
| Myalgia | Musculoskeletal and connective tissue disorders | MedDRA 18.0 | Systematic Assessment |
|
| Pain in extremity | Musculoskeletal and connective tissue disorders | MedDRA 18.0 | Systematic Assessment |
|
| Dizziness | Nervous system disorders | MedDRA 18.0 | Systematic Assessment |
|
| Headache | Nervous system disorders | MedDRA 18.0 | Systematic Assessment |
|
| Confusional state | Psychiatric disorders | MedDRA 18.0 | Systematic Assessment |
|
| Nervousness | Psychiatric disorders | MedDRA 18.0 | Systematic Assessment |
|
| Restlessness | Psychiatric disorders | MedDRA 18.0 | Systematic Assessment |
|
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA 18.0 | Systematic Assessment |
|
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | MedDRA 18.0 | Systematic Assessment |
|
| Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | MedDRA 18.0 | Systematic Assessment |
|
| Eyelid oedema | Skin and subcutaneous tissue disorders | MedDRA 18.0 | Systematic Assessment |
|
| Hyperhidrosis | Skin and subcutaneous tissue disorders | MedDRA 18.0 | Systematic Assessment |
|
| Rash | Skin and subcutaneous tissue disorders | MedDRA 18.0 | Systematic Assessment |
|
| Duodenal ulcer | Gastrointestinal disorders | MedDRA 18.0 | Systematic Assessment |
|
Written consent
| D004700 | Endocrine System Diseases |